Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 63


Therapeutic sensitivity to Rac GTPase inhibition requires consequential suppression of mTORC1, AKT, and MEK signaling in breast cancer.

Hampsch RA, Shee K, Bates D, Lewis LD, Désiré L, Leblond B, Demidenko E, Stefan K, Huang YH, Miller TW.

Oncotarget. 2017 Mar 28;8(13):21806-21817. doi: 10.18632/oncotarget.15586.


Bayesian model of signal rewiring reveals mechanisms of gene dysregulation in acquired drug resistance in breast cancer.

Azad AK, Lawen A, Keith JM.

PLoS One. 2017 Mar 13;12(3):e0173331. doi: 10.1371/journal.pone.0173331. eCollection 2017.


Reconstruction of Gene Regulatory Networks based on Repairing Sparse Low-rank Matrices.

Chang YH, Dobbe R, Bhushan P, Gray JW, Tomlin CJ.

IEEE/ACM Trans Comput Biol Bioinform. 2016 Jul-Aug;13(4):767-777. Epub 2015 Aug 7.


HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target?

Galdy S, Lamarca A, McNamara MG, Hubner RA, Cella CA, Fazio N, Valle JW.

Cancer Metastasis Rev. 2017 Mar;36(1):141-157. doi: 10.1007/s10555-016-9645-x.


Overcoming resistance to HER2 inhibitors through state-specific kinase binding.

Novotny CJ, Pollari S, Park JH, Lemmon MA, Shen W, Shokat KM.

Nat Chem Biol. 2016 Nov;12(11):923-930. doi: 10.1038/nchembio.2171. Epub 2016 Sep 5.


Epigenetic inhibition of adaptive bypass responses to lapatinib by targeting BET Bromodomains.

Stuhlmiller TJ, Miller SM, Johnson GL.

Mol Cell Oncol. 2015 Jun 10;3(1):e1052182. doi: 10.1080/23723556.2015.1052182. eCollection 2016 Jan.


Intermolecular biparatopic trapping of ErbB2 prevents compensatory activation of PI3K/AKT via RAS-p110 crosstalk.

Tamaskovic R, Schwill M, Nagy-Davidescu G, Jost C, Schaefer DC, Verdurmen WP, Schaefer JV, Honegger A, Plückthun A.

Nat Commun. 2016 Jun 3;7:11672. doi: 10.1038/ncomms11672.


Translating neoadjuvant therapy into survival benefits: one size does not fit all.

De Mattos-Arruda L, Shen R, Reis-Filho JS, Cortés J.

Nat Rev Clin Oncol. 2016 Sep;13(9):566-79. doi: 10.1038/nrclinonc.2016.35. Epub 2016 Mar 22. Review.


Effective treatment of HER2-amplified breast cancer by targeting HER3 and β1 integrin.

Campbell MR, Zhang H, Ziaee S, Ruiz-Saenz A, Gulizia N, Oeffinger J, Amin DN, Ahuja D, Moasser MM, Park CC.

Breast Cancer Res Treat. 2016 Feb;155(3):431-40. doi: 10.1007/s10549-016-3698-y. Epub 2016 Feb 9.


Strategically Timing Inhibition of Phosphatidylinositol 3-Kinase to Maximize Therapeutic Index in Estrogen Receptor Alpha-Positive, PIK3CA-Mutant Breast Cancer.

Yang W, Hosford SR, Dillon LM, Shee K, Liu SC, Bean JR, Salphati L, Pang J, Zhang X, Nannini MA, Demidenko E, Bates D, Lewis LD, Marotti JD, Eastman AR, Miller TW.

Clin Cancer Res. 2016 May 1;22(9):2250-60. doi: 10.1158/1078-0432.CCR-15-2276. Epub 2016 Jan 5.


Efficacy and mechanism of action of the tyrosine kinase inhibitors gefitinib, lapatinib and neratinib in the treatment of HER2-positive breast cancer: preclinical and clinical evidence.

Segovia-Mendoza M, González-González ME, Barrera D, Díaz L, García-Becerra R.

Am J Cancer Res. 2015 Aug 15;5(9):2531-61. eCollection 2015. Review.


Lapatinib Plasma and Tumor Concentrations and Effects on HER Receptor Phosphorylation in Tumor.

Spector NL, Robertson FC, Bacus S, Blackwell K, Smith DA, Glenn K, Cartee L, Harris J, Kimbrough CL, Gittelman M, Avisar E, Beitsch P, Koch KM.

PLoS One. 2015 Nov 16;10(11):e0142845. doi: 10.1371/journal.pone.0142845. eCollection 2015.


Intermittent high-dose treatment with erlotinib enhances therapeutic efficacy in EGFR-mutant lung cancer.

Schöttle J, Chatterjee S, Volz C, Siobal M, Florin A, Rokitta D, Hinze Y, Dietlein F, Plenker D, König K, Albus K, Heuckmann JM, Rauh D, Franz T, Neumaier B, Fuhr U, Heukamp LC, Ullrich RT.

Oncotarget. 2015 Nov 17;6(36):38458-68. doi: 10.18632/oncotarget.6276.


Chemical probing of HER2-amplified cancer cells identifies TORC2 as a particularly effective secondary target for combination with lapatinib.

Amin DN, Ruiz-Saenz A, Gulizia N, Moasser MM.

Oncotarget. 2015 Dec 1;6(38):41123-33. doi: 10.18632/oncotarget.5660.


A TORC2-Akt Feed-Forward Topology Underlies HER3 Resiliency in HER2-Amplified Cancers.

Amin DN, Ahuja D, Yaswen P, Moasser MM.

Mol Cancer Ther. 2015 Dec;14(12):2805-17. doi: 10.1158/1535-7163.MCT-15-0403. Epub 2015 Oct 5.


Dynamical modeling of uncertain interaction-based genomic networks.

Mohsenizadeh DN, Hua J, Bittner M, Dougherty ER.

BMC Bioinformatics. 2015;16 Suppl 13:S3. doi: 10.1186/1471-2105-16-S13-S3. Epub 2015 Sep 25.


Microenvironment rigidity modulates responses to the HER2 receptor tyrosine kinase inhibitor lapatinib via YAP and TAZ transcription factors.

Lin CH, Pelissier FA, Zhang H, Lakins J, Weaver VM, Park C, LaBarge MA.

Mol Biol Cell. 2015 Nov 5;26(22):3946-53. doi: 10.1091/mbc.E15-07-0456. Epub 2015 Sep 2.


Decoupling of the PI3K Pathway via Mutation Necessitates Combinatorial Treatment in HER2+ Breast Cancer.

Korkola JE, Collisson EA, Heiser L, Oates C, Bayani N, Itani S, Esch A, Thompson W, Griffith OL, Wang NJ, Kuo WL, Cooper B, Billig J, Ziyad S, Hung JL, Jakkula L, Feiler H, Lu Y, Mills GB, Spellman PT, Tomlin C, Mukherjee S, Gray JW.

PLoS One. 2015 Jul 16;10(7):e0133219. doi: 10.1371/journal.pone.0133219. eCollection 2015.


Disentangling multidimensional spatio-temporal data into their common and aberrant responses.

Chang YH, Korkola J, Amin DN, Moasser MM, Carmena JM, Gray JW, Tomlin CJ.

PLoS One. 2015 Apr 22;10(4):e0121607. doi: 10.1371/journal.pone.0121607. eCollection 2015.


Inhibition of Lapatinib-Induced Kinome Reprogramming in ERBB2-Positive Breast Cancer by Targeting BET Family Bromodomains.

Stuhlmiller TJ, Miller SM, Zawistowski JS, Nakamura K, Beltran AS, Duncan JS, Angus SP, Collins KA, Granger DA, Reuther RA, Graves LM, Gomez SM, Kuan PF, Parker JS, Chen X, Sciaky N, Carey LA, Earp HS, Jin J, Johnson GL.

Cell Rep. 2015 Apr 21;11(3):390-404. doi: 10.1016/j.celrep.2015.03.037. Epub 2015 Apr 9.

Supplemental Content

Support Center